Kerem Ozer
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1982878617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $181,321 of the $219,992 with a category attached, or 82.4%. Lilly USA, LLC accounts for 63.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $137,931 and has fallen 99.9% since, to $187 in 2023. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $439.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$139K
- Novo Nordisk$38K
- AstraZeneca$15K
- Boehringer Ingelheim$12K
- Johnson & Johnson$5K
- Sanofi-aventis U.S. LLC$4K
- plus $8K from 15 others
Across 673 payments — averaging $3068.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$778K
- Abbott$384K
- AbbVie$330K
- Medtronic$300K
- Novo Nordisk AS$106K
- Senseonics, Incorporated$93K
- plus $75K from 3 others
What the payments were for
- Consulting fees$16,7048%
- Speaking & faculty fees$181,32182%
- Travel & lodging$15,6787%
- Food & beverage$6,2783%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 355 | $139,275 |
| Novo Nordisk | 58 | $38,345 |
| AstraZeneca | 21 | $14,620 |
| Boehringer Ingelheim | 23 | $11,987 |
| Johnson & Johnson | 7 | $4,568 |
| Sanofi-aventis U.S. LLC | 2 | $3,621 |
| IBSA Pharma Inc. | 9 | $2,614 |
| Dexcom, Inc. | 2 | $2,426 |
| Clarus Therapeutics Inc. | 2 | $2,150 |
| Medtronic(2 entities) | 3 | $67 |
| Tandem Diabetes Care, Inc. | 4 | $44 |
| Abbott | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $37 |
| Insulet Corporation | 2 | $35 |
| Nevro Corp. | 1 | $34 |
| Radius Health, Inc. | 2 | $26 |
| Amgen | 1 | $20 |
| AbbVie | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$67,643
- JARDIANCE$26,062
- BAQSIMI$24,950
- Ozempic$14,730
- FARXIGA$14,347
- Tresiba$10,521
- JATENZO$6,450
- INVOKANA$4,530
- Tirosint$4,000
- SOLIQUA 100/33$3,604
- DEXCOM CGM$2,426
- RYBELSUS$2,312
- LYUMJEV$2,200
- Tirosint-SOL$1,000
- Saxenda$115
How this compares
$219,992 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Round Rock
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.